Biventricular Epicardial Augmentation Technology A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
- Coordinator
- Adjucor GmbH, Germany
- Runs
- 1 January 2023 to 31 December 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €3.9m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190170931
What the project is doing
In the project's own words, from its summary on CORDIS.
Over 500K patients in the EU and US suffer from end-stage heart failure (HF), with a life expectancy of <1 year in 38% of cases. The prevalence of HF has increased recently, mainly due to improved survival after heart attacks. Such patients require mechanical support of their hearts. Available treatment options are heart transplantation (HTX) and ventricular assist device (VAD). Today, <3% of these patients are treated due to donor heart shortages and restrictive employment of VADs.
VADs can cause severe complications, such as bleeding and strokes, and typically only support one side of the heart. reBEAT is a revolutionary technology to mechanically support both sides of the heart, does not directly contact blood and can be easily implanted (~40 minutes). It presents virtually no contraindications for the patient population described. reBEAT offers high cost effectiveness at <50% of the cost of heart transplantations and VADs.
AdjuCor expects revenues of 69M€ by 2027 with reBEAT.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Adjucor GmbH | Munchen | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI